Perrigo agrees to exclusive licensing agreement for Highland’s Tarex technology

Perrigo Co. this week announced that it has agreed to an exclusive licensing agreement with Highland Pharmaceuticals LLC for its methamphetamine (meth) blocking technology called Tarex.

The agreement also includes the distribution rights of Zephrex D, which was developed using the Tarex technology, and has proven more than 98 percent effective at hindering various types of domestic ways to produce illegal meth.

"Across the country, illegal methamphetamine use continues to be a significant issue," Perrigo EVP and President of Consumer Healthcare, Americas, Jeff Needham said. "Our investment in Tarex technology is another example of Perrigo's commitment to help protect and promote healthier communities. We are committed to leveraging the Tarex technology to extend our line of meth-resistant pseudoephedrine products in the future."

The agreement with Highland is part of Perrgio's commitment to stop meth abuse. The company has planned to put the Tarex technology into a variety of its own pseudoephedrine HCI products with store brand and retailer labels over time. Retail customers will be able to buy Zephrex D, which wil be distributed immediately.